Zarontin is a prescription drug claimed to be effective in reducing seizures and epilepsy treatment. It is presented as an anticonvulsant succinimide indicated for the control of absence (petit mal) epilepsy.
Zarontin’s manufacturer is Pfizer, an American multinational pharmaceutical corporation and one of the largest companies in this industry, worldwide. It has been established in 1849 and started out as a chemical business producing and selling a single product, the antiparasitic called Santonin. The company has been involved in several lawsuits such as illegally marketing several drugs or unapproved human testing with experimental drugs.
The presence of multiple, potentially fatal side-effects recommend Zarontin as a drug prescribed mostly as a last resort treatment when other medicine has failed to return positive results.
Zarontin capsules includes the following ingredients: Ethosuximide (active ingredient), Polyethylene glycol 400, D&C yellow No. 10, FD&C red No.3, gelatin, glycerin, USP, and sorbitol.
Zarontin oral solution includes the following ingredients: 250 mg Ethosuximide for each 5 ml (teaspoonful) of oral solution, citric acid, anhydrous, FD&C red No. 40, FD&C yellow No. 6, flavor; glycerin, purified water, saccharin sodium, USP, sodium benzoate, sodium citrate, and sucrose.
Zarontin is a prescription drug based on the active ingredient ethosuximide, a substance used alone or with other medications to prevent and control a certain type of seizure. The mechanism of action is by controlling the abnormal electrical activity in the brain which occurs during a seizure. Its most common side effects are: drowsiness, headache, dizziness, tiredness, stomach upset, nausea, vomiting, loss of appetite, weight loss, diarrhea and loss of coordination.
More severe side-effects include increased risk of suicidal thoughts or behavior in patients using for any indication, severe liver or renal damage and clinically proven cause for elevated incidence of children with birth defects born to women who used ethosuximide during pregnancy.
The initial recommended dose for patients 3 to 6 years of age is one teaspoonful (250 mg) per day; for patients 6 years of age and older, 2 teaspoonfuls (500 mg) per day. The dose thereafter must be individualized according to the patient’s response, but only as prescribed.
- The drug is FDA approved
- There are some clinical studies to support some of the manufacturer’s claims
- Reputable international manufacturer
- Zarontin is associated with numerous dangerous side effects
- The formula may interact with other antiepileptic drugs
Zarontin (ethosuximide) is a drug prescribed for the control of absence (petit mal) seizures, also known as epilepsy. However ethosuximide, when used alone in mixed types of epilepsy may increase the frequency of grand mal seizures in some patients.
The product’s effect consists in reducing the frequency of epileptiform attacks. It is a prescription drug which should be used with extreme caution and only under a healthcare professional’s supervision. As with other anticonvulsants, it is essential to be very careful when increasing or decreasing dosage, and should be done incrementally. Abrupt withdrawal of anticonvulsant medication may aggravate absence (petit mal) status.
Zarontin may impair the mental and/or physical abilities (alertness, clear thinking) required for the performance of potentially hazardous tasks (driving a motor vehicle).